X-linked adrenoleukodystrophy, usually shortened to X-ALD, is a rare inherited disorder that can affect the brain, spinal cord, peripheral nerves, and adrenal glands. That is a surprisingly long list for one altered gene, but X-ALD has never been interested in keeping things simple.
The condition is caused by harmful changes in the ABCD1 gene. These changes interfere with the body’s ability to process certain fats known as very long-chain fatty acids. As the fats accumulate, they can contribute to inflammation, damage the protective myelin surrounding nerves, and disrupt hormone production by the adrenal glands.
What makes X-ALD especially challenging is its unpredictability. Two relatives with the same genetic variant may develop very different symptoms, at different ages, and at different rates. Some boys develop rapidly progressive cerebral disease during childhood. Some men experience a slower spinal cord condition in adulthood. Others first show signs of adrenal insufficiency, while many girls and women remain symptom-free until later adulthood or develop milder neurological problems.
Early diagnosis matters because certain treatments are most effective before significant neurological damage occurs. Newborn screening, genetic testing, scheduled brain imaging, and adrenal monitoring have therefore become central parts of modern X-ALD care.
What Is X-Linked Adrenoleukodystrophy?
X-ALD is a genetic metabolic disorder and a type of leukodystrophy. Leukodystrophies primarily affect white matter, the tissue containing nerve fibers wrapped in myelin. Myelin works somewhat like insulation around electrical wiring: it helps signals travel quickly and accurately through the nervous system.
When myelin becomes inflamed or deteriorates, communication between the brain and the rest of the body can slow down or fail. Depending on which areas are affected, a person may experience behavioral changes, learning difficulties, muscle stiffness, weakness, vision problems, seizures, or loss of coordination.
X-ALD can also damage the adrenal cortex. The adrenal glands sit above the kidneys and produce cortisol, a hormone needed for blood pressure, metabolism, immune responses, and the body’s reaction to illness or injury. Insufficient cortisol production can become life-threatening during infection, surgery, dehydration, or physical stress.
What Causes X-ALD?
The Role of the ABCD1 Gene
X-ALD develops because of a disease-causing variant in the ABCD1 gene on the X chromosome. This gene provides instructions for producing the adrenoleukodystrophy protein, often called ALDP.
ALDP helps transport very long-chain fatty acids into peroxisomes. Peroxisomes are tiny structures inside cells that act like biological recycling centers, breaking down fats and other substances. When ALDP is missing or does not function correctly, very long-chain fatty acids accumulate in tissues and body fluids.
Elevated fatty-acid levels are an important diagnostic marker, but the number on a laboratory report cannot predict exactly how the disease will behave. A person’s specific ABCD1 variant also cannot reliably forecast whether cerebral disease, adrenal insufficiency, or adult myelopathy will develop. Genetics supplies the diagnosis, but unfortunately not a crystal ball.
How X-Linked Inheritance Works
Because the altered gene is located on the X chromosome, X-ALD usually affects boys and men more severely. Males generally have one X chromosome, so one disease-causing variant can leave them without a normally functioning copy of ABCD1.
Females generally have two X chromosomes. A normally functioning copy of the gene may partially compensate for the altered copy, but this protection is not complete. Many women who carry an ABCD1 variant eventually develop stiffness, walking difficulties, pain, balance problems, or bladder symptoms, particularly later in adulthood.
A woman with an ABCD1 variant has a 50% chance of passing that variant to each child. A man with X-ALD passes his X chromosome to all his daughters and none of his sons. New genetic changes can also arise without a previously recognized family history.
The Main Forms of X-ALD
Childhood Cerebral ALD
Cerebral adrenoleukodystrophy, or cerebral ALD, is the most rapidly progressive form. It most commonly begins during childhood, although cerebral disease can also start in adolescents and adults.
Inflammation damages myelin in the brain, sometimes progressing over months or a few years. Early symptoms may appear deceptively ordinary. A child may seem distracted, struggle at school, become unusually impulsive, or have difficulty processing spoken instructions. These changes can initially resemble attention-deficit disorder, a learning disability, hearing trouble, or an especially dramatic case of “I forgot my homework.”
Possible symptoms include:
- Declining school performance
- Behavioral or personality changes
- Difficulty concentrating or understanding speech
- Problems with vision or hearing
- Poor coordination and an unsteady gait
- Weakness or muscle stiffness
- Difficulty swallowing or speaking
- Seizures
- Progressive loss of previously acquired abilities
Brain MRI changes may appear before noticeable neurological symptoms. This is why routine surveillance is so important for boys diagnosed through newborn screening or family testing.
Adrenomyeloneuropathy
Adrenomyeloneuropathy, commonly called AMN, is a slower neurological form that generally appears in adult men. It primarily affects long nerve pathways in the spinal cord and legs.
Symptoms often begin with mild stiffness, balance trouble, or the feeling that the legs are not quite cooperating. Progression usually occurs over years rather than months.
Common AMN symptoms include:
- Progressive stiffness or spasticity in the legs
- Leg weakness and difficulty walking
- Frequent tripping or balance problems
- Numbness, altered sensation, or nerve pain
- Bladder urgency, frequency, or incontinence
- Bowel dysfunction
- Sexual dysfunction
- Fatigue and reduced physical endurance
Some men with AMN later develop cerebral inflammation. Regular neurological evaluations and brain MRI surveillance may therefore remain necessary even when symptoms initially involve only the spinal cord.
Adrenal Insufficiency
Adrenal insufficiency may occur alone or alongside neurological disease. In some boys and men, it is the first recognizable sign of X-ALD.
Symptoms can include:
- Persistent fatigue or muscle weakness
- Reduced appetite and unexplained weight loss
- Nausea, abdominal pain, vomiting, or diarrhea
- Low blood pressure, dizziness, or fainting
- Low blood sugar
- Salt cravings
- Darkening of the skin, particularly in creases or scars
An adrenal crisis is a medical emergency. Severe vomiting, dehydration, confusion, extreme weakness, very low blood pressure, or loss of consciousness requires immediate treatment. People with known adrenal insufficiency typically need an emergency steroid plan for illness, injuries, surgery, and other physical stress.
X-ALD in Girls and Women
Girls and women with an ABCD1 variant were historically described simply as “carriers.” That label can be misleading because many develop neurological symptoms themselves.
Symptoms usually begin later than they do in men and may resemble a slowly progressive myelopathy. Leg stiffness, weakness, balance difficulties, chronic pain, bladder problems, and reduced mobility are common concerns. Cerebral ALD and adrenal insufficiency are much less common in females, but new or unusual symptoms still deserve specialist evaluation.
How X-ALD Is Diagnosed
Newborn Screening
X-ALD is included on the U.S. Recommended Uniform Screening Panel, although the exact disorders screened can vary by state or territory. Screening commonly measures a substance called C26:0-lysophosphatidylcholine in a dried blood sample.
A positive newborn screen is not a final diagnosis. Follow-up testing is needed to confirm elevated very long-chain fatty acids, identify an ABCD1 variant, and rule out other metabolic disorders. A baby identified through screening will usually appear completely healthy, which is precisely why screening is valuable: it creates time for surveillance before a crisis or neurological decline begins.
Blood and Genetic Tests
Diagnostic testing may include measurements of very long-chain fatty acids, adrenal hormones, electrolytes, and genetic analysis of ABCD1. Genetic testing can confirm the diagnosis and support testing of parents, siblings, and other relatives who may also be at risk.
Biochemical testing alone may be less reliable in some females, making molecular genetic testing particularly important when there is a family history or suggestive symptoms.
Brain MRI and Neurological Testing
Brain MRI can detect white-matter changes and active inflammation before severe symptoms appear. Specialists may use an MRI scoring system to estimate the extent of cerebral involvement and determine whether treatment should be considered.
Neurological examinations, neuropsychological testing, vision and hearing assessments, gait evaluations, and physical-function measurements can help identify subtle changes that might otherwise be dismissed as clumsiness, stress, aging, or a bad week.
Adrenal Testing
Adrenal monitoring typically involves blood tests such as morning cortisol and adrenocorticotropic hormone, or ACTH. Additional stimulation testing may be needed when results are unclear.
Ongoing testing is essential because a normal result today does not guarantee normal adrenal function indefinitely.
Treatment for X-Linked Adrenoleukodystrophy
There is no single treatment that addresses every form of X-ALD. Care depends on the person’s age, symptoms, MRI findings, adrenal function, disease stage, and overall health.
Hematopoietic Stem Cell Transplantation
Allogeneic hematopoietic stem cell transplantation may slow or stop early cerebral ALD by replacing blood-forming cells with healthy donor cells. Over time, donor-derived cells can enter the brain and help reduce the damaging inflammatory process.
Timing is critical. Transplantation offers the greatest potential benefit when MRI changes are detected early and neurological function remains relatively preserved. It cannot reliably restore brain tissue that has already been extensively damaged.
Transplantation also carries serious risks, including infection, organ complications, graft failure, infertility, and graft-versus-host disease. Treatment decisions should be made by an experienced multidisciplinary transplant and leukodystrophy team.
Gene Therapy
Elivaldogene autotemcel, marketed as Skysona, is an FDA-approved gene therapy intended to slow neurological progression in eligible boys ages 4 through 17 with early, active cerebral ALD who do not have an available HLA-matched donor for allogeneic stem cell transplantation.
The procedure uses the patient’s own blood-forming stem cells. The cells are collected, modified in a laboratory to carry a functioning copy of the gene, and returned after conditioning chemotherapy.
Gene therapy avoids graft-versus-host disease because the patient receives his own modified cells. However, it is not risk-free. The FDA strengthened safety labeling in August 2025 because of an increased risk of serious blood cancers following treatment. Patients require careful risk-benefit discussions and long-term blood monitoring after therapy.
Hormone Replacement for Adrenal Insufficiency
Corticosteroid replacement, often with hydrocortisone or another glucocorticoid, replaces hormones the adrenal glands cannot produce adequately. Some patients may also need mineralocorticoid replacement.
Hormone therapy can prevent adrenal crises and control endocrine symptoms, but it does not treat cerebral inflammation or spinal cord degeneration. Patients and caregivers should receive instructions about stress dosing, emergency injections, medical identification, and when to seek urgent care.
Managing AMN and Neurological Symptoms
There is currently no established therapy that reverses AMN. Treatment focuses on maintaining mobility, independence, safety, and comfort.
A care plan may include:
- Physical and occupational therapy
- Stretching and strengthening exercises
- Medication for spasticity or nerve pain
- Bladder and bowel management
- Sexual-health treatment
- Braces, canes, walkers, wheelchairs, or other mobility equipment
- Fall-prevention strategies
- Speech, swallowing, or respiratory support when needed
- Mental-health and social-work services
Mobility equipment is not a declaration of defeat. Used at the right time, it can conserve energy, prevent injuries, and make room for work, parenting, travel, and everything else a person would prefer to do instead of repeatedly negotiating with an uncooperative staircase.
Diet and Lorenzo’s Oil
Lorenzo’s oil is a mixture of specific fatty acids developed to reduce very long-chain fatty-acid levels. It may lower those levels in the blood, but it has not been shown to reverse established neurological damage or replace MRI surveillance, transplantation, gene therapy, or adrenal treatment.
Some specialist centers may discuss it in selected presymptomatic patients. It should be used only under medical and nutritional supervision because dietary oils can cause complications and require laboratory monitoring. Simply removing fat from the diet does not correct the underlying transport problem.
Monitoring and Long-Term Care
X-ALD care is often best coordinated through a center with expertise in metabolic genetics, neurology, endocrinology, neuropsychology, rehabilitation, and stem cell transplantation.
A long-term plan may involve scheduled brain MRIs, adrenal testing, neurological examinations, developmental or cognitive assessments, physical-function testing, and genetic counseling. Surveillance frequency varies by age, sex, symptoms, and previous test results.
Families should also keep an updated emergency plan, medication list, specialist contact information, and copies of important MRI and genetic reports. Rare-disease care occasionally requires becoming the world’s most reluctant filing-cabinet enthusiast.
Experiences of Living With X-ALD
When a Newborn Screen Changes the Family Calendar
For many families, the first experience of X-ALD begins with a telephone call about an abnormal newborn screen. The baby may be feeding normally, sleeping normally, and displaying no visible sign of illness. Parents can feel confused by the idea that an apparently healthy child needs endocrinology appointments, genetic testing, and years of brain MRI surveillance.
The first months may involve equal parts gratitude and anxiety. Early detection gives the child access to monitoring that can identify adrenal insufficiency or cerebral changes before permanent injury occurs. At the same time, each future appointment acquires emotional weight. An MRI calendar can feel like a subscription nobody remembers ordering.
Families often report that clear written schedules make the uncertainty more manageable. Knowing which tests are due, who will review the results, and what would trigger treatment turns a vague threat into a defined plan.
Watchful Waiting Is Not Passive
The phrase “watchful waiting” can sound as though everyone is simply standing around and hoping for the best. In X-ALD, surveillance is active medical care.
A child may have regular MRIs despite feeling well because imaging abnormalities can precede obvious symptoms. Parents may quietly monitor schoolwork, hearing, coordination, behavior, and stamina without wanting every forgotten backpack to become a neurological emergency.
This balancing act can be exhausting. Families benefit from clinicians who explain which changes deserve an immediate phone call and which belong on a list for the next appointment. Schools can also help by documenting meaningful changes in attention, learning, behavior, vision, hearing, or physical abilities.
The Adult Experience Can Be Gradual but Disruptive
Adults with AMN may notice changes so slowly that they adapt without realizing how much effort daily life has begun to require. Someone may avoid uneven sidewalks, stop joining coworkers for long walks, choose seats near restrooms, or take extra time to recover after routine activities.
Balance problems, fatigue, pain, bladder symptoms, and leg weakness can affect employment, relationships, exercise, travel, and self-confidence. Patient-reported research has found that mobility limitations, balance difficulties, fatigue, leg weakness, and fear of progression are among the most significant burdens described by adults with ALD.
Rehabilitation can help people work with the function they have rather than waiting for a dramatic decline. A therapist may suggest stretching routines, energy-conservation techniques, home modifications, or mobility aids before falls become frequent. These small interventions can produce very practical victories: fewer injuries, less fatigue, and more energy for activities that actually matter.
Women Often Face Delayed Recognition
Women with X-ALD sometimes spend years being told that they are merely genetic carriers. When stiffness, pain, balance trouble, or bladder symptoms develop, those problems may be attributed to aging, orthopedic conditions, menopause, or lack of exercise.
Recognition can bring relief as well as frustration. A diagnosis validates the symptoms, but effective disease-modifying treatment for the spinal form remains limited. A coordinated plan involving neurology, rehabilitation, pain management, pelvic-health specialists, and mental-health support can still improve function and quality of life.
One Diagnosis Can Reveal an Entire Family Story
Because X-ALD is inherited, one diagnosis may lead to testing across several generations. A newborn’s result may explain an uncle’s unexplained adrenal illness, a grandfather’s walking difficulties, or a female relative’s progressive stiffness.
These discoveries can create guilt, relief, grief, and urgency at the same time. Genetic counselors help families understand that nobody chooses which genes they inherit or pass on. The practical goal is not to assign blame; it is to identify relatives who may benefit from adrenal testing, neurological surveillance, reproductive counseling, or early treatment.
Living Well Requires More Than Medical Procedures
Specialist treatment is important, but daily life is shaped by ordinary details: accessible transportation, school support, bathroom planning, insurance approvals, exercise that feels safe, reliable caregivers, and clinicians who return messages.
Support groups and rare-disease organizations can connect families with people who understand the odd combination of medical vocabulary, uncertainty, and administrative paperwork that comes with X-ALD. Counseling may also help patients and caregivers manage anticipatory grief, treatment decisions, and the fear that every new symptom signals progression.
There is no universal X-ALD experience. Some people remain stable for long periods, while others face rapid changes. The most useful approach is individualized: monitor what can be monitored, treat what can be treated, prepare for emergencies, and make decisions with a team that understands the disease.
Conclusion
X-linked adrenoleukodystrophy is a complex genetic disorder with several possible presentations. It may cause rapidly progressive cerebral inflammation, chronic spinal cord disease, adrenal insufficiency, or later-onset neurological symptoms in women.
Because symptoms and timing cannot be predicted reliably from the genetic variant alone, lifelong monitoring is essential. Newborn screening and family testing can identify people before symptoms begin, while scheduled MRI and adrenal evaluations create opportunities for early intervention.
Stem cell transplantation and gene therapy may slow early cerebral ALD in carefully selected patients, while hormone replacement can prevent life-threatening adrenal crises. Rehabilitation, symptom management, mobility support, genetic counseling, and psychological care remain important across the full X-ALD spectrum.
Note: This article is for general educational purposes and is not a substitute for diagnosis or treatment from a qualified medical professional. Suspected X-ALD, adrenal crisis symptoms, abnormal newborn screening results, or new neurological changes require prompt evaluation by an experienced healthcare team. The content was synthesized from current information provided by GeneReviews and NCBI, NIH and MedlinePlus, GARD, NINDS, the FDA, HRSA, ACMG, peer-reviewed consensus recommendations, Mayo Clinic, Cleveland Clinic, Johns Hopkins Medicine, Boston Children’s Hospital, Children’s Hospital of Philadelphia, ALD Connect, and published patient-impact research.
